Aptagen, LLC
Aptamer F5R1 against a-Synuclein in Parkinson’s Disease (ID# 9527)
DNA
a-Synuclein in Parkinson's Disease
Protein
2.40 nM (reported value)
PBS, 1 mM MgCI2, pH 7.4
25°C
heated at 95°C for 3 min and then gradually cooled to 25°C at a rate of 5°C per min
N/A
N/A
5'-dApdTpdCpdGpdApdGpdTpdGpdTpdGpdTpdApdCpdGpdGpdGpdGpdTpdCpdCpdGpdGpdTpdApdGpdGpdGpdTpdGpdGpdCpdGpdApdGpdGpdTpdCpdTpdTpdCpdCpdTpdGpdTpdCpdGpdTpdApdGpdCpdApdGpdGpdApdTpdCpdCpdAp-3'
60
18057.7 g/mole
560900 L/(mole·cm)
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Zheng, Y., Qu, J., Xue, F., Zheng, Y., Yang, B., Chang, Y., Yang, H., & Zhang, J. (2018). Novel DNA Aptamers for Parkinson's Disease Treatment Inhibit α-Synuclein Aggregation and Facilitate its Degradation. Molecular therapy. Nucleic acids, 11, 228–242. https://doi.org/10.1016/j.omtn.2018.02.011
Have your aptamer oligo synthesized ORDER
We are always looking for ways to improve. Please tell us what you think.